Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report

G. Chowaniecova, P. Berzinec, G. Kosturiakova, L. Plank, A. Farkasova, M. Sekeresova, D. Juskanic, D. Ondrus

. 2022 ; 166 (4) : 451-454. [pub] 20220823

Jazyk angličtina Země Česko

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc22029531

BACKGROUND: Transformation of EGFR (epidermal growth factor receptor) - mutant non-small cell lung cancer (NSCLC) into small-cell lung cancer (SCLC) is one mechanism of resistance to tyrosine kinase inhibitor (TKI) treatment, seen in approximately 3-10% cases. Such transformed SCLC often retains the original EGFR mutation (EGFRM), which is not otherwise observed in SCLC. CASE REPORT: We present a 67 y/o woman with pulmonary adenocarcinoma (AC) and EGFRM deletion on exon 19. After initial treatment with whole brain radiotherapy and 7 months of TKI afatinib, progression was observed. Liquid biopsy detected deletion on exon 19 and T790M mutation. Chemotherapy carboplatin plus pemetrexed was administered, with no response. Genetics from a rebiopsy of lung revealed deletion on exon 19. After 12 months treatment with TKI osimertinib, a progression in lung and pancreas lesions was detected, docetaxel was used, with followig progression. The lung biopsy revealed SCLC. Significant elevation of serum markers carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) was observed at the time of the SCLC diagnosis. Treatment with carboplatin and etoposide was not effective. The next biopsy found two populations of cells: SCLC and AC. The biopsy from the pancreatic lesion revealed metastasis of SCLC. PCR confirmed EGFRM deletion on exon 19 in the lung SCLC tissue sample. The following treatment lines of topotecan, erlotinib were not effective. The patient survived 36 months from diagnosis, 7 months from detection of SCLC. CONCLUSION: Screening for transformation of EGFR-mutant NSCLC to SCLC should be considered in resistance to TKI. In the presented case, this rare transformation was confirmed by histopathologic examination and by PCR. EGFRM in the lung SCLC, identical to that found in the original lung AC, was detected. Further, the observed elevation of serum tumor markers NSE and CEA can indicate this infrequent transformation and help to decide on rebiopsy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22029531
003      
CZ-PrNML
005      
20230118155256.0
007      
ta
008      
230113s2022 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2022.037 $2 doi
035    __
$a (PubMed)36036563
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Chowaniecová, Gabriela $u Department of Oncology, Specialised Hospital of St Zoerardus Zobor, Nitra, Slovak Republik $u 1st Department of Oncology, Faculty of Medicine, Comenius University and St. Elisabeth Cancer Institute, Bratislava, Slovak Republik $7 _AN072735
245    13
$a An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report / $c G. Chowaniecova, P. Berzinec, G. Kosturiakova, L. Plank, A. Farkasova, M. Sekeresova, D. Juskanic, D. Ondrus
520    9_
$a BACKGROUND: Transformation of EGFR (epidermal growth factor receptor) - mutant non-small cell lung cancer (NSCLC) into small-cell lung cancer (SCLC) is one mechanism of resistance to tyrosine kinase inhibitor (TKI) treatment, seen in approximately 3-10% cases. Such transformed SCLC often retains the original EGFR mutation (EGFRM), which is not otherwise observed in SCLC. CASE REPORT: We present a 67 y/o woman with pulmonary adenocarcinoma (AC) and EGFRM deletion on exon 19. After initial treatment with whole brain radiotherapy and 7 months of TKI afatinib, progression was observed. Liquid biopsy detected deletion on exon 19 and T790M mutation. Chemotherapy carboplatin plus pemetrexed was administered, with no response. Genetics from a rebiopsy of lung revealed deletion on exon 19. After 12 months treatment with TKI osimertinib, a progression in lung and pancreas lesions was detected, docetaxel was used, with followig progression. The lung biopsy revealed SCLC. Significant elevation of serum markers carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) was observed at the time of the SCLC diagnosis. Treatment with carboplatin and etoposide was not effective. The next biopsy found two populations of cells: SCLC and AC. The biopsy from the pancreatic lesion revealed metastasis of SCLC. PCR confirmed EGFRM deletion on exon 19 in the lung SCLC tissue sample. The following treatment lines of topotecan, erlotinib were not effective. The patient survived 36 months from diagnosis, 7 months from detection of SCLC. CONCLUSION: Screening for transformation of EGFR-mutant NSCLC to SCLC should be considered in resistance to TKI. In the presented case, this rare transformation was confirmed by histopathologic examination and by PCR. EGFRM in the lung SCLC, identical to that found in the original lung AC, was detected. Further, the observed elevation of serum tumor markers NSE and CEA can indicate this infrequent transformation and help to decide on rebiopsy.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a erbB receptory $x genetika $x terapeutické užití $7 D066246
650    12
$a nemalobuněčný karcinom plic $x genetika $7 D002289
650    _2
$a karboplatina $x terapeutické užití $7 D016190
650    _2
$a karcinoembryonální antigen $x genetika $x terapeutické užití $7 D002272
650    12
$a nádory plic $x farmakoterapie $x genetika $x patologie $7 D008175
650    _2
$a inhibitory proteinkinas $7 D047428
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a mutace $7 D009154
650    12
$a malobuněčný karcinom plic $x genetika $x farmakoterapie $x patologie $7 D055752
650    12
$a adenokarcinom plic $x genetika $x farmakoterapie $7 D000077192
655    _2
$a kazuistiky $7 D002363
700    1_
$a Beržinec, Peter, $u Department of Oncology, Specialised Hospital of St Zoerardus Zobor, Nitra, Slovak Republik $d 1958- $7 xx0105021
700    1_
$a Kosturiakova, Gabriela $u Department of Pneumology and Phtiseology, Specialised Hospital of St Zoerardus Zobor, Nitra, Slovak Republik
700    1_
$a Plank, Lukáš, $u Department of Pathological Anatomy, Jessenius Faculty of Medicine, Comenius University and University Hospital in Martin, Martin, Slovak Republik $u Martin's Biopsy Centre Ltd, Martin, Slovak Republik $d 1951- $7 nlk20020104017
700    1_
$a Farkašová, Anna $u Martin's Biopsy Centre Ltd, Martin, Slovak Republik $7 xx0229982
700    1_
$a Sekerešová, M. $u Department of Pathology, Faculty Hospital, Nitra, Slovak Republik $7 xx0276001
700    1_
$a Juskanic, Dominik $u Radiology, Jessenius - Diagnostic Centre, Nitra, Slovak Republik $u Department of Radiology, Faculty of Medicine, Comenius University and Slovak Medical University, University Hospital, Bratislava, Slovak Republic
700    1_
$a Ondruš, Dalibor, $u 1st Department of Oncology, Faculty of Medicine, Comenius University and St. Elisabeth Cancer Institute, Bratislava, Slovak Republik $d 1953- $7 xx0051658
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 166, č. 4 (2022), s. 451-454
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36036563 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20230113 $b ABA008
991    __
$a 20230118155251 $b ABA008
999    __
$a ok $b bmc $g 1885627 $s 1180856
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 166 $c 4 $d 451-454 $e 20220823 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK138 $a Pubmed-20230113
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace